Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|December 10, 2018
FDA Approves Celltrion and Teva’s Biosimilar to Rituxan
Author(s)Pharmaceutical Technology Editors
FDA has approved Truxima (rituximab-abbs), a biosimilar to Roche’s anti-cancer biologic, Rituxan (rituximab).
Advertisement
Celltrion and Teva Pharmaceutical Industries announced on Nov. 29, 2018 that FDA approved Truxima (rituximab-abbs), a biosimilar referencing Roche’s anti-cancer biologic, Rituxan (rituximab). Rituxan is Roches’ top-selling drug with
According to Celltrion, Truxima is the first rituximab biosimilar to be approved in the United States. The drug was approved for three indications: as a single agent to treat relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non–Hodgkin’s lymphoma (NHL); in combination with chemotherapy for previously untreated follicular, CD20-positive, B-cell NHL and as single-agent maintenance therapy for the same condition in patients achieving a complete or partial response to a rituximab product; and as a single-agent for treating non-progressing, low-grade, CD20-positive, B-cell NHL.
“Truxima is the very first rituximab biosimilar to be approved in the United States for three non-Hodgkin’s lymphoma indications and may help provide greater accessibility for patients,” said Woosung Kee, CEO of Celltrion, in a company press release.
Celltrion and Teva entered into an exclusive partnership in October 2016 to commercialize Truxima in the US and Canada. The two companies have reached a settlement agreement with Genentech, a Roche company, including entry terms. The terms and conditions of the agreement were not disclosed.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement